Skip to main content
Joseph Jurcic, MD, Oncology, New York, NY

JosephGJurcicMD

Oncology New York, NY

Hematologic Oncology

Professor of Medicine at Columbia University Irving Medical Center Director, Hematologic Malignancies Section, Div. of Hematology/Oncology New York-Presbyterian Hospital/Columbia University Irving Medical Center

Overview of Dr. Jurcic

I am currently Professor of Medicine at Columbia University Medical Center and Director of the Hematologic Malignancies Section of the Division of Hematology/Oncology. Prior to joining the faculty at Columbia University Medical Center in January, 2013, I was an Attending Physician on the Leukemia Service at Memorial Sloan-Kettering Cancer Center for over 18 years. My main focus is the treatment of acute and chronic leukemias, myeloproliferative neoplasms, and myelodysplastic syndrome. My research interests include acute myeloid leukemia, radioimmunotherapy with alpha and beta particle-emitting radioisotopes, monoclonal antibody-based therapies for leukemia, the development of novel small molecule inhibitors for leukemia, and the molecular monitoring of minimal residual disease. I am the 2001 recipient of the Louis and Allston Boyer Young Investigator Award for Distinguished Achievement in Biomedical Research from Memorial Sloan-Kettering Cancer Center. I am author or coauthor of more than 90 articles and book chapters, have been the principal investigator on over 40 clinical trials, and regularly lecture at national and international meetings. I served as a Leukemia Section Editor for The Oncologist from 2007-2015.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1991 - 1994
  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1988 - 1991
  • Perelman School of Medicine at the University of Pennsylvania
    Perelman School of Medicine at the University of PennsylvaniaClass of 1988
  • University of Pittsburgh
    University of PittsburghBS, Mathematics & Philosophy, Summa cum laude, 1979 - 1984

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1991 - 2026
  • NJ State Medical License
    NJ State Medical License 2012 - 2015
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • New York Magazine: Top Doctors Castle Connolly, 2014-2024
  • Top Doctors: New York Metro Area Castle Connolly, 2007-2023
  • America's Top Doctors Castle Connolly, 2010-2021
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Na¥ve Patients with Higher-Risk Myelodysplastic Syndrome
    Joseph G. Jurcic, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Combination Thioguanine and Decitabine Is Highly Active in Patients with Advanced Myeloid Malignancies: A Single Institution Experience
    Joseph G. Jurcic, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Tr... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • A Phase 2 Study of Actinium-225 (225Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Alpha Particle Therapy of Hematologic Malignanices 
    26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona, Spain - 11/2014
  • Join now to see all

Press Mentions

  • Actinium Pharmaceuticals Unveils New Clinical Trial for Leukemia with Its Treatment Actimab-A
    Actinium Pharmaceuticals Unveils New Clinical Trial for Leukemia with Its Treatment Actimab-AJune 28th, 2018
  • Actinium (NYSE: $ATNM) Announces Initiation of Phase 2 Clinical Trial of Actimab-A in Patients Newly Diagnosed with Acute Myeloid Leukemia over Age 60
    Actinium (NYSE: $ATNM) Announces Initiation of Phase 2 Clinical Trial of Actimab-A in Patients Newly Diagnosed with Acute Myeloid Leukemia over Age 60September 27th, 2016
  • Actinium KOL Joseph Jurcic, MD to Discuss the Role of Actinium’s Alpha-Particle Radiopharmaceuticals in the Treatment of Leukemia Patients at the 2014 Society of Nuclear Medicine and Molecular Imaging Annual Meeting
    Actinium KOL Joseph Jurcic, MD to Discuss the Role of Actinium’s Alpha-Particle Radiopharmaceuticals in the Treatment of Leukemia Patients at the 2014 Society of Nuclear Medicine and Molecular Imaging Annual MeetingJune 5th, 2014
  • Join now to see all

Committees

  • Member, Education Committee, Society of Hematologic Oncology 2013 - Present
  • Member, Southwest Oncology Group, Leukemia Committee and Leukemia Committee Working Group 2013 - Present
  • Member, Scientific Program Committee on Leukemia, Myelodysplasia, and Transplantation, American Society of Clinical Oncology 2014 - 2016

Professional Memberships

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    BCBS Blue Card PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Empire BCBS HMO
    Empire BCBS PPO
    GHI PPO
    Great West PPO
    Humana ChoiceCare Network PPO
    Multiplan PHCS PPO
    Multiplan PPO
    MVP Healthcare PPO
    Oxford Health Freedom
    Oxford Health Liberty
    QualCare HMO
    QualCare PPO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment